Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Interferon Stories

2013-01-31 12:28:53

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) - world's leading supporter of innovative research in lupus -- today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years. In just its first decade of service, the LRI has awarded more than $40 million for novel...

2013-01-17 08:26:00

RIDGEFIELD, Conn., Jan. 17, 2013 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc. announced that the first patients have been enrolled in the company's pivotal Phase 3 interferon (IFN)-free hepatitis C (HCV) clinical trial program, HCVerso(TM). Boehringer Ingelheim's investigational IFN-free regimen combines the compounds faldaprevir (BI 201335), a protease inhibitor administered once-daily, and BI 207127, a non-nucleoside polymerase inhibitor administered twice-daily, plus...

2013-01-08 14:51:39

A metanalysis published in BioMed Central's open access journal BMC Medicine has confirmed that polymorphisms (SNP) in the gene coding for interleukin-28 (IL28B) influence natural hepatitis C viral (HCV) clearance and response to pegylated interferon-α plus ribavirin (PEG-IFN/RBV). Information about IL28B genotype could be used to provide personalized medicine and target treatment options effectively. Over 200 million people worldwide are chronically infected with hepatitis C...

2013-01-03 13:36:00

New research published in the Journal of Leukocyte Biology suggests that Porphyromonas gingivalis causes excess IL-10 production, which inhibits the immune cells interferon gamma leading to infection A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease--Porphyromonas gingivalis--manipulates the body's immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this...

2013-01-03 12:24:27

ROCKLAND, Mass. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif(®) Rebidose(®) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo:...

2013-01-03 08:27:02

BURLINGTON, Mass., Jan. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, from 2011 to 2021, growth in the hepatitis B virus (HBV) drug market will be driven by continued uptake of oral nucleoside/nucleotide analogues, such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread. However, the entry of generic Baraclude in 2015 and 2016 in the United States and Europe,...

2013-01-03 08:25:52

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that it has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) that requests permission to initiate a clinical feasibility study of Hepatitis-C (HCV) infected individuals enrolled to receive Hemopurifier®...

2012-11-23 10:53:50

Ribosome-mapping technique may provide insights into other viral proteomes as well New findings reveal the surprisingly complex protein-coding capacity of the human cytomegalovirus, or HCMV, and provide the first steps toward understanding how the virus manipulates human cells during infection. The genome of the HCMV was first sequenced over 20 years ago, but researchers have now investigated the proteome–the complete set of expressed proteins–of this common pathogen as well....

2012-11-19 08:28:59

LONDON, Nov. 19, 2012 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood...

2012-11-15 11:36:10

Influenza curbs part of the immune system and abets bacterial infections When infected with influenza, the body becomes an easy target for bacteria. The flu virus alters the host's immune system and compromises its capacity to effectively fight off bacterial infections. Now, a team of immunologists at the Helmholtz Centre for Infection Research (HZI) and cooperation partners has discovered that an immune system molecule called TLR7 is partly to blame. The molecule recognizes the viral...


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »